Trial Profile

The DIPAK 1 Study: A Randomised, Controlled Clinical Trial Assessing the Efficacy of Lanreotide to Halt Disease Progression in ADPKD

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 10 Feb 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lanreotide (Primary)
Indications Autosomal dominant polycystic kidney disease
Focus Therapeutic Use
Acronyms DIPAK1

Most Recent Events

29 Mar 2021 Results (n=249) of a post-hoc analysis assessing the incidence of gallstones on imaging and related complications in unbiased trial data, published in the Drugs in R and D
22 Apr 2019 Results of a subanalysis from this trial published in the Gastroenterology
25 Oct 2018 Results assessing effect of Lanreotide on kidney function published in the JAMA: the Journal of the American Medical Association.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com